These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19246725)

  • 1. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch.
    Lefèvre G; Büche M; Sedek G; Maton S; Enz A; Lorch U; Sagan C; Appel-Dingemanse S
    J Clin Pharmacol; 2009 Apr; 49(4):430-43. PubMed ID: 19246725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
    Lefèvre G; Sedek G; Jhee SS; Leibowitz MT; Huang HL; Enz A; Maton S; Ereshefsky L; Pommier F; Schmidli H; Appel-Dingemanse S
    Clin Pharmacol Ther; 2008 Jan; 83(1):106-14. PubMed ID: 17522596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application.
    Lefèvre G; Sedek G; Huang HL; Saltzman M; Rosenberg M; Kiese B; Fordham P
    J Clin Pharmacol; 2007 Apr; 47(4):471-8. PubMed ID: 17389556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine exposure provided by a transdermal patch versus capsules.
    Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
    Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.
    Kurz A; Farlow M; Lefèvre G
    Int J Clin Pract; 2009 May; 63(5):799-805. PubMed ID: 19392927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic rationale for the rivastigmine patch.
    Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
    Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rivastigmine patch for dementia.
    Med Lett Drugs Ther; 2008 Mar; 50(1282):21-2. PubMed ID: 18356801
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease.
    Winblad B; Machado JC
    Expert Opin Drug Deliv; 2008 Dec; 5(12):1377-86. PubMed ID: 19040398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats.
    Yang ZZ; Zhang YQ; Wu K; Wang ZZ; Qi XR
    Curr Alzheimer Res; 2012 Mar; 9(3):315-25. PubMed ID: 22044027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivastigmine transdermal patch: role in the management of Alzheimer's disease.
    Guay DR
    Consult Pharm; 2008 Aug; 23(8):598-609. PubMed ID: 19032006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.
    Grossberg G; Sadowsky C; Fröstl H; Frölich L; Nagel J; Tekin S; Zechner S; Ros J; Orgogozo JM
    Alzheimer Dis Assoc Disord; 2009; 23(2):158-64. PubMed ID: 19484917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.
    Shua-Haim J; Smith J; Picard F; Sedek G; Athalye S; Pommier F; Lefèvre G
    Clin Drug Investig; 2008; 28(6):361-74. PubMed ID: 18479178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
    Dhillon S
    Drugs; 2011 Jun; 71(9):1209-31. PubMed ID: 21711064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
    Greenspoon J; Herrmann N; Adam DN
    CNS Drugs; 2011 Jul; 25(7):575-83. PubMed ID: 21623641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
    Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
    Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.
    Dhillon S
    Drugs Aging; 2011 Nov; 28(11):927-30. PubMed ID: 22054233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.
    Lefèvre G; Pommier F; Sedek G; Allison M; Huang HL; Kiese B; Ho YY; Appel-Dingemanse S
    J Clin Pharmacol; 2008 Feb; 48(2):246-52. PubMed ID: 18199897
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.